Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.

IF 4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2026-04-30 DOI:10.1007/s12325-026-03568-6

Anju T Peters, Andréanne Côté, Xavier Muñoz, Changming Xia, Scott Nash, Megan Hardin, Lucía de Prado Gómez, Harry J Sacks, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz

{"title":"Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.","authors":"Anju T Peters, Andréanne Côté, Xavier Muñoz, Changming Xia, Scott Nash, Megan Hardin, Lucía de Prado Gómez, Harry J Sacks, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz","doi":"10.1007/s12325-026-03568-6","DOIUrl":null,"url":null,"abstract":"Introduction: Coexisting type 2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type 2 inflammatory diseases in these patients.Methods: Patients aged ≥ 12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1 month and thereafter every 3 months for up to 3 years, per standard of care across study sites.Results: At the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type 2 coexisting disease) ranged from 42.3 to 57.3 years and mean body mass index from 29.9 to 31.8 kg/m2. Most patients were female (67.3% to 77.4%), and mean time since asthma diagnosis was 17.3 to 24.0 years, with mean duration of coexisting diseases ranging from 9.8 to 17.0 years. A total of 189 (92%) patients had ≥ 1 ongoing type 2 coexisting disease (AR, 80%; CRS and/or NP, 45% [CRS with NP, 47%; CRS without NP, 41%; NP, 12%]; AD, 27%; urticaria, 15%; and EoE, 3%).Conclusion: This analysis from the RAPID registry shows that type 2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.Trial registration: ClinicalTrials.gov: NCT04287621.","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-026-03568-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Coexisting type 2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type 2 inflammatory diseases in these patients.

Methods: Patients aged ≥ 12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1 month and thereafter every 3 months for up to 3 years, per standard of care across study sites.

Results: At the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type 2 coexisting disease) ranged from 42.3 to 57.3 years and mean body mass index from 29.9 to 31.8 kg/m². Most patients were female (67.3% to 77.4%), and mean time since asthma diagnosis was 17.3 to 24.0 years, with mean duration of coexisting diseases ranging from 9.8 to 17.0 years. A total of 189 (92%) patients had ≥ 1 ongoing type 2 coexisting disease (AR, 80%; CRS and/or NP, 45% [CRS with NP, 47%; CRS without NP, 41%; NP, 12%]; AD, 27%; urticaria, 15%; and EoE, 3%).

Conclusion: This analysis from the RAPID registry shows that type 2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.

Trial registration: ClinicalTrials.gov: NCT04287621.

查看原文本刊更多论文

Dupilumab治疗哮喘患者并发2型炎症：RAPID注册

共存的2型炎症性疾病，如过敏性鼻炎（AR）、特应性皮炎（AD）、慢性鼻窦炎（CRS）和/或鼻息肉病（NP）、嗜酸性食管炎（EoE）和荨麻疹在哮喘中很常见。RAPID （NCT04287621）是一项全球前瞻性注册研究，旨在对哮喘患者在真实世界的临床环境中启动dupilumab进行表征。本分析调查了这些患者中共存的2型炎性疾病的患病率。方法：年龄≥12岁的患者根据国家特定处方信息开始dupilumab治疗哮喘（主要指征），纳入RAPID。患者在1个月后进行定期评估，此后每3个月进行一次评估，持续3年。结果：在分析时，纳入了205例患者。患者的平均年龄（按2型共存疾病分层）为42.3至57.3岁，平均体重指数为29.9至31.8 kg/m2。大多数患者为女性（67.3% ~ 77.4%），自哮喘诊断的平均时间为17.3 ~ 24.0年，平均共存疾病持续时间为9.8 ~ 17.0年。共有189例（92%）患者存在≥1种持续的2型共存疾病（AR, 80%； CRS和/或NP， 45% [CRS合并NP， 47%； CRS无NP， 41%； NP, 12%]； AD, 27%；荨麻疹，15%;EoE, 3%）。结论：来自RAPID注册的分析显示，在临床实践环境中，2型共存疾病在哮喘患者中非常普遍，并且强调了正确评估患者以改善患者护理的重要性。试验注册：ClinicalTrials.gov: NCT04287621。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.